Melanoma Research
Pembrolizumab demonstrates high pathologic response rates in desmoplastic melanoma patients who had not received prior systemic therapy.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- The Clinical Trial Landscape for Melanoma Therapies
- Melanoma: Pathogenesis and Targeted Therapy